Medication Monitor



Generic Name (Trade Name—Company)
Notes
December 5, 2017

Ixekizumab

(Taltz—Eli Lilly)
Active psoriatic arthritis is second approved indication for agent

FDA has approved ixekizumab injection 80 mg/mL for the treatment of adults with active psoriatic arthritis. The agent was first approved in March 2016 for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Ixekizumab injection may be administered alone or in combination with a conventional disease-modifying antirheumatic drug, such as methotrexate. It should not be used in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

The agent may increase the risk of infection. Other warnings and precautions include pretreatment evaluation for tuberculosis, hypersensitivity reactions, inflammatory bowel disease, and immunizations.

Most common adverse reactions associated with treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profile observed in patients with psoriatic arthritis was consistent with the safety profile in patients with plaque psoriasis, with the exception of influenza and conjunctivitis.